Markus Lacher

Markus Lacher has over 20 years of experience in the biotechnology industry. Markus began their career in 2001 as a Postdoctoral Researcher and Assistant Researcher/Specialist at the University of California, San Francisco, where they investigated TGF-beta-mediated epithelial-to-mesenchymal transition (EMT) and the reverse, mesenchymal-to-epithelial transition (MET), in cancer. In 2009, they joined OncoCyte Corporation (a BioTime, Inc. subsidiary) as a Scientist and Consultant. In 2012, they founded and served as CEO and President of T cell Therapeutics, Inc., a biotechnology company dedicated to developing and commercializing immunotherapies for the selective ablation of cancer cells resistant to standard treatments. In 2014, they joined Cesca Therapeutics, Inc. as a Senior Clinical Scientist. In 2015, they joined BriaCell Therapeutics Corp. as a Senior Director of Research and Development, where they led successful preclinical to clinical development of Bria-IMT (SV-BR-1-GM), an allogeneic, whole-cell, experimental drug for breast cancer immunotherapy. Markus currently serves as Vice President of R&D and Head of Immuno-Oncology at Notable since 2020.

Markus Lacher obtained a Master of Science - MS in Microbiology from the University of Bern in 1998, followed by a Doctor of Philosophy - PhD in Molecular Biology from the same university in 2001. In October 2021, they obtained a Cybersecurity Awareness Training certification from ESET North America.